Skip to content

Acrivastine

Histamine-1 Receptor Antagonist — RESPIRATORY SYSTEM

Also known as: BW-270C, BW-825C, semprex

OfmFDA approvedATC R06AX18

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Acrivastine is an ofm drug in the Histamine-1 Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1994. Its mechanism of action is classified as Histamine H1 Receptor Antagonists. DrugCentral lists 3 molecular targets, including HRH1, HRH1 and ABCB1. Recorded indications include Allergic conjunctivitis, Allergic rhinitis, Common cold and Nasal congestion.

  • Approval status: ofm (first approved 1994 by the FDA).
  • Drug class: Histamine-1 Receptor Antagonist.
  • Mechanism of action: Histamine H1 Receptor Antagonists.
  • Molecular targets: HRH1, HRH1 and ABCB1 (3 listed in DrugCentral).
  • Indications: Allergic conjunctivitis, Allergic rhinitis, Common cold, Nasal congestion and Nasal discharge and others.
  • ATC code: R06AX18 (Other antihistamines for systemic use).
  • Molecular formula: C22H24N2O2; molecular weight 348.45 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (8)

  • Allergic conjunctivitis
  • Allergic rhinitis
  • Common cold
  • Nasal congestion
  • Nasal discharge
  • Seasonal allergic rhinitis
  • Sneezing
  • Vasomotor rhinitis

Contraindications (8)

  • Angle-closure glaucoma
  • Benign prostatic hyperplasia
  • Coronary arteriosclerosis
  • Diabetes mellitus
  • Hypertensive disorder
  • Hypertensive urgency
  • Hyperthyroidism
  • Retention of urine

Mechanism & targets

Mechanism of action (MoA)Histamine H1 Receptor Antagonists
Established pharmacologic classHistamine-1 Receptor Antagonist

Molecular targets (3)

TargetGeneActionActivity
Histamine H1 receptorHRH1antagonistIC50 7.16
Histamine H1 receptorHRH1unknownIC50 5.21
Multidrug resistance protein 1ABCB1unknown—

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1994-03-25FDA—AUXILIUM PHARMS INC

ATC classification

ATC codeTherapeutic hierarchy
R06AX18RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Other antihistamines for systemic use

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Total lung capacity increased382.9
Asthma-chronic obstructive pulmonary disease overlap syndrome363.3
Hypomania338.4
Jaundice cholestatic315.3
Nasal polyps298.0
Sarcoidosis297.7
Rhinitis allergic277.5
Schizophrenia273.8
Cardiac murmur237.9
Bronchiectasis218.4
Psychotic disorder208.1
Lung neoplasm malignant198.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Acrivastine is on its molecule page.

Molecular formulaC22H24N2O2
Molecular weight348.45 g/mol
CAS number87848-99-5
InChIKeyPWACSDKDOHSSQD-IUTFFREVSA-N
PubChem CID5284514
CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC(\C=C\C(O)=O)=N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Acrivastine used for?

DrugCentral lists the following indications for Acrivastine: Allergic conjunctivitis, Allergic rhinitis, Common cold, Nasal congestion, Nasal discharge, Seasonal allergic rhinitis, Sneezing and Vasomotor rhinitis.

How does Acrivastine work?

Acrivastine is classified as Histamine H1 Receptor Antagonists; its molecular targets in DrugCentral include HRH1 (antagonist), HRH1 and ABCB1.

When was Acrivastine first approved?

Acrivastine was first approved by the FDA in 1994.

What drug class does Acrivastine belong to?

Acrivastine is in the Histamine-1 Receptor Antagonist class.

What is the chemical formula of Acrivastine?

Acrivastine has the molecular formula C22H24N2O2 and a molecular weight of 348.45 g/mol.

Browse: all drugs starting with A · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFM
First approval1994-03-25
AgencyFDA
Targets3
Indications8
FormulaC22H24N2O2
DrugCentral ID82
Interactive profile